Please join the Crinetics management team for a R&D Day to discuss the Company’s proprietary in-house discovery engine and proven development approach for differentiated endocrine therapies.

The event will highlight Crinetics’ early-stage pipeline strategy and data to deliver sustainable long-term growth, with a focus on:

• NETs and beyond – NDC platform with CRN09682
• TSH antagonist for Graves’ disease and thyroid eye disease (TED)
• SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD)